Effects of mifepristone (RU486) treatment on the development of uterine adenomyosis induced by pituitary grafting in mice
article
OA: closed
CC0
⤵ 17 in-corpus citations
AI-generated summary
This study investigated the effects of mifepristone treatment on uterine adenomyosis that developed in mice after pituitary grafting.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
To evaluate the effects of mifepristone (RU486) on the development of uterine adenomyosis induced by pituitary grafting (PG), 3 groups of mice receiving pituitary grafts at 7 weeks of age were given RU486 in food (20 mg/kg chow) from 3-14 (RU486-3 group) or 10-14 (RU486-10 group) weeks of age, or were given no further treatment (PG control group), respectively. All the mice were killed at 14 weeks of age. The uterine weight was significantly decreased in both RU486-treated groups compared with the PG control group. The incidence of adenomyosis was also decreased significantly in both the RU486-3 group (0/10 mice) and RU486-10 group (2/10 mice) compared with the PG control group (7/9 mice). To look for vascular changes in the uterine tissues, which have been reported to be related to the development of adenomyosis, immunohistochemical staining of von Willebrand factor in the blood vessels was performed. The mean surface area and minor axis of blood vessels in the uterus were thereby found to be significantly decreased in the RU486-10 group compared to the PG control group. The results clearly indicated that RU486, a potent antiprogestin, could inhibit the genesis of uterine adenomyosis in mice, and at the same time caused shrinkage of the vascular system. As in humans, progesterone as well as the vascular system therefore appear to be important factors in the pathogenesis of uterine adenomyosis in this mouse model.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (16)
- Exploring the Endocrine Mechanisms in Adenomyosis: From Pathogenesis to Therapies 2024
- Exploring the Endocrine Mechanisms in Adenomyosis: From Pathogenesis to Therapies 2024
- Effect of Mifepristone vs Placebo for Treatment of Adenomyosis With Pain Symptoms: A Randomized Clinical Trial 2023
- Investigation of the 12-month efficacy and safety of low-dose mifepristone in the treatment of painful adenomyosis 2022
- Mifepristone Treats Symptomatic Adenomyosis: A Multicentre, Randomized, Double-Blind and Placebo-Controlled Trial 2021
- Animal Models of Adenomyosis 2020
- Ulipristal acetate use in adenomyosis: A randomized controlled trial 2020
- Improving the Preclinical Mouse Efficacy Studies of Adenomyosis 2015
- Adenomiosis: tratamiento 2015
- Methodological Issues in Preclinical Mouse Efficacy Studies of Adenomyosis 2012
- Traitement de l'adénomyose 2007
- Tratamiento de la adenomiosis 2007
- Current diagnostic and treatment strategies for adenomyosis 2006
- Évolutions physiopathologiques, diagnostiques et thérapeutiques dans la prise en charge de l’adénomyose : revue de la littérature 2004
- Probucol, a hypocholesterolemic agent, prevents the development of uterine adenomyosis induced by pituitary grafting in mice. 2004
- Effects of angiogenesis inhibitor TNP-470 on the development of uterine adenomyosis in mice 2003
Source provenance
- europepmc
- last seen: 2026-09-20T09:27:46.357103+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:13:30.513821+00:00
License: CC0
· commercial use OK